An "unconventional" immune response now identified by scientists from the Hackensack Meridian Center for Discovery and Innovation (CDI) is a potential new pathway for developing new vaccines for tuberculosis (TB), according to a new publication.

Scientists from the Hackensack Meridian Center for Discovery and Innovation, working with collaborators from across the globe, uncovered the mechanism of action of a novel anti-tuberculosis drug that they have helped develop.